Stryker Co. (NYSE:SYK) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Stryker Co. (NYSE:SYK - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the twenty brokerages that are presently covering the firm, Marketbeat.com reports. Four research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $420.68.

SYK has been the subject of several research reports. Citigroup upped their price objective on shares of Stryker from $411.00 to $450.00 and gave the company a "buy" rating in a research note on Wednesday, December 11th. Truist Financial upped their price target on Stryker from $409.00 to $413.00 and gave the company a "hold" rating in a research report on Thursday, January 30th. Robert W. Baird boosted their price objective on Stryker from $378.00 to $405.00 and gave the stock an "outperform" rating in a research note on Wednesday, October 30th. Needham & Company LLC restated a "buy" rating and issued a $442.00 target price on shares of Stryker in a report on Wednesday, January 29th. Finally, JMP Securities reiterated a "market perform" rating on shares of Stryker in a report on Tuesday.

Insider Buying and Selling

In related news, Director Allan C. Golston sold 2,458 shares of Stryker stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total value of $941,586.06. Following the completion of the transaction, the director now owns 14,895 shares in the company, valued at $5,705,827.65. The trade was a 14.16 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Ronda E. Stryker sold 201,392 shares of the stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the completion of the sale, the director now directly owns 3,642,075 shares in the company, valued at approximately $1,428,567,498. This represents a 5.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.90% of the stock is owned by insiders.

Hedge Funds Weigh In On Stryker

A number of institutional investors and hedge funds have recently modified their holdings of SYK. Stratos Wealth Advisors LLC lifted its stake in Stryker by 3.4% during the third quarter. Stratos Wealth Advisors LLC now owns 4,177 shares of the medical technology company's stock worth $1,509,000 after purchasing an additional 139 shares during the last quarter. Net Worth Advisory Group purchased a new stake in shares of Stryker during the 3rd quarter worth approximately $571,000. Moss Adams Wealth Advisors LLC boosted its holdings in shares of Stryker by 8.4% in the 3rd quarter. Moss Adams Wealth Advisors LLC now owns 751 shares of the medical technology company's stock valued at $272,000 after buying an additional 58 shares in the last quarter. Blue Trust Inc. raised its stake in Stryker by 23.8% during the 3rd quarter. Blue Trust Inc. now owns 7,792 shares of the medical technology company's stock worth $2,651,000 after acquiring an additional 1,498 shares in the last quarter. Finally, Capital Investment Advisors LLC lifted its position in Stryker by 102.5% in the third quarter. Capital Investment Advisors LLC now owns 1,855 shares of the medical technology company's stock valued at $670,000 after acquiring an additional 939 shares during the last quarter. Institutional investors and hedge funds own 77.09% of the company's stock.

Stryker Price Performance

Stryker stock traded down $2.05 during midday trading on Monday, reaching $386.47. The company had a trading volume of 930,252 shares, compared to its average volume of 1,392,508. Stryker has a 12-month low of $314.93 and a 12-month high of $406.19. The firm's fifty day simple moving average is $377.69 and its 200-day simple moving average is $368.08. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.95 and a quick ratio of 1.32. The company has a market capitalization of $147.47 billion, a P/E ratio of 49.80, a P/E/G ratio of 2.90 and a beta of 0.96.

Stryker (NYSE:SYK - Get Free Report) last issued its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, topping the consensus estimate of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same quarter in the previous year, the business earned $3.46 earnings per share. As a group, equities analysts anticipate that Stryker will post 13.49 EPS for the current year.

Stryker Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be paid a dividend of $0.84 per share. The ex-dividend date is Monday, March 31st. This represents a $3.36 dividend on an annualized basis and a yield of 0.87%. Stryker's dividend payout ratio (DPR) is presently 43.30%.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.